Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of Illumina stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $205.93, for a total transaction of $411,860.00. Following the completion of the sale, the executive vice president now owns 36,179 shares of the company’s stock, valued at approximately $7,450,341.47. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Marc Stapley also recently made the following trade(s):

  • On Thursday, August 3rd, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $196.80, for a total transaction of $393,600.00.
  • On Friday, July 14th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $173.56, for a total transaction of $347,120.00.
  • On Monday, June 12th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $170.85, for a total transaction of $341,700.00.

Illumina, Inc. (NASDAQ:ILMN) traded up 1.34% during trading on Thursday, reaching $210.20. 757,035 shares of the company’s stock were exchanged. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $211.27. The firm has a 50 day moving average of $191.38 and a 200-day moving average of $178.42. The stock has a market cap of $30.69 billion, a PE ratio of 42.17 and a beta of 0.81.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. During the same period last year, the company earned $0.86 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. On average, equities research analysts anticipate that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.

WARNING: “Illumina, Inc. (ILMN) EVP Sells $411,860.00 in Stock” was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/07/illumina-inc-ilmn-evp-sells-411860-00-in-stock.html.

Large investors have recently modified their holdings of the company. Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Illumina by 1.4% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock valued at $528,000 after acquiring an additional 43 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Illumina by 41.0% during the first quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock valued at $1,056,000 after acquiring an additional 1,800 shares in the last quarter. State of Tennessee Treasury Department increased its holdings in shares of Illumina by 7.8% during the first quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock valued at $16,697,000 after acquiring an additional 7,040 shares in the last quarter. Paradigm Asset Management Co. LLC increased its holdings in shares of Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after acquiring an additional 50 shares in the last quarter. Finally, Bank of Nova Scotia increased its holdings in shares of Illumina by 265.4% during the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock valued at $14,710,000 after acquiring an additional 62,612 shares in the last quarter. Hedge funds and other institutional investors own 93.34% of the company’s stock.

Several research firms have recently weighed in on ILMN. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price objective for the company in a research note on Tuesday, June 27th. BidaskClub lowered shares of Illumina from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $250.00 price objective on shares of Illumina in a research note on Wednesday, August 2nd. Finally, First Analysis upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price objective for the company in a research note on Wednesday, August 2nd. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the stock. Illumina has a consensus rating of “Hold” and a consensus target price of $177.01.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.